Under the terms of the deal, Beijing-based GeneCast has the exclusive right to market Agendia's MammaPrint and BluePrint tests to Chinese customers.
The company said it plans to use the financing to increase adoption of its MammaPrint BluePrint next-generation sequencing-based test kit for breast cancer.
Under the deal, Singapore-based Angsana Molecular & Diagnostics Laboratory will offer the two tests in markets including Singapore.
Unicancer will provide patients with centralized laboratory testing performed by Agendia, and also adopt the company's NGS kits for decentralized testing.
The coverage decisions follow similar decisions by Blue Shield of California and First Coast Service Options last year.
The change will be felt most immediately in Europe, where the Dutch molecular diagnostics company recently secured a CE-IVD mark for its MammaPrint BluePrint kit.
The company hopes that meeting the needs of a more decentralized testing model will increase access to its products for European women with breast cancer.
Although a draft guidance last month recommended against use of molecular tests to guide chemotherapy, the group's finalized decision is subject to price negotiation and other adjustments.
The NGS kit combines Agendia's MammaPrint 70-gene breast cancer recurrence risk test and its BluePrint breast cancer subtyping assay.
The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.
Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.
Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.
In Science this week: in vitro generation of human reproductive cells, and more.